BERKELEY, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Stephen K. Doberstein, Ph.D., to the position of Vice President of Research. In this position, Dr. Doberstein will be responsible for directing XOMA's preclinical drug candidates through the discovery and development process, where he will focus on antibody discovery and cell line development. He will also support the clinical development of XOMA's portfolio of drug candidates through his direction of non-clinical safety, translational medicine and pharmacokinetics or pharmacodynamics experiments.
